Talk Description

This presentation will outline the mission, structure, and impact of the Division of Therapeutics and Medical Consequences (DTMC), established in response to a 1989 Congressional mandate to advance medication development for substance use disorders (SUDs). It will describe how DTMC, modeled after a virtual pharmaceutical company, supports all phases of therapeutic development—from discovery through regulatory approval—to improve the management of SUDs and their medical consequences, including HIV. The presentation will highlight DTMC’s strategic focus on developing safe and effective medications, biologics, devices, digital therapeutics, and behavioral therapies; its collaborations with industry and federal partners; its regulatory engagement with the FDA; and its record of notable contributions to advancing the treatment for opioid, stimulant, cannabis, and nicotine use disorders. The presentation will include opportunities for collaborations with DTMC and funding opportunities to conduct research in this therapeutic development for SUDs.

Iván D. Montoya, M.D., M.P.H

Iván D. Montoya is Director of the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse (NIDA), NIH, where he leads a national and international research portfolio focused on developing medications, biologics, behavioral interventions, devices, and digital therapeutics for substance use disorders and studying their medical consequences. A physician–scientist and public health leader, he has extensive expertise in translational addiction research, multi-site clinical trials, and pharmacotherapy development. Dr. Montoya has authored numerous peer-reviewed publications and has received multiple honors, including the Lifetime Achievement Award from the American Society of Hispanic Psychiatry, the Michael Morrison Award from the College on Problems of Drug Dependence,  HHS Secretary’s Award for Distinguished Service, and several NIH and NIDA Director’s Awards. He has authored numerous peer-reviewed publications and has edited major reference works in addiction medicine.